The Federal Government of Nigeria has taken a significant step towards reducing the cost of medicines and improving access to healthcare commodities nationwide by operationalising Medipool as the country’s National Group Purchasing Organisation (GPO). This initiative, formalized through a Memorandum of Understanding, will coordinate bulk purchases of medicines to achieve lower costs.

According to the Federal Ministry of Health and Social Welfare, the operationalisation of Medipool will facilitate bulk purchasing, price negotiation, and improved quality assurance across Nigeria’s health supply chain. The scheme aligns with key national priorities, including the Basic Healthcare Provision Fund, the Presidential Initiative to Unlock the Healthcare Value Chain, and the National Health Supply Chain Transformation Plan.

The operationalisation of Medipool follows the Federal Executive Council’s approval of the initiative in May 2025. Prof. Ali Pate explained that the project will initially operate through the Basic Health Care Provision Fund and federal tertiary hospitals.

Medipool is expected to leverage pooled demand to negotiate better prices with manufacturers and suppliers, while monitoring quality standards across the supply chain. The initiative also supports the government’s target of increasing local pharmaceutical production to meet a larger share of domestic demand.

Officials say the GPO will improve procurement transparency, reduce inefficiencies in medicine distribution, and ensure essential health commodities reach health facilities more reliably. The system is also designed to strengthen financial protection for patients by lowering out-of-pocket expenses on medicines.

The cost of medicines in Nigeria has escalated sharply in recent years. Nairametrics reports that essential drugs such as anti-malaria medications rose by over 135% and insulin and some antibiotics by up to 157% in late 2024, largely driven by inflation and the weakening naira.

These rising costs have placed additional pressure on hospitals, prompting many to increase service tariffs and health insurance premiums, with some HMOs raising annual plan costs by nearly 60 percent between 2024 and 2025.

Prescription medicines and healthcare services have generally become more expensive, often outpacing general inflation, while hospital admissions, diagnostic tests, and other essential services have also seen significant price increases.